Seattle biotech startup Curi Bio, which enables the screening of new drugs using cells and 3D tissue models derived from human cells, announced $10 million in new funding.
Curi Bio’s customers include large biopharmaceutical and biotech companies such Novo Nordisk, Eli Lilly, Astrazeneca, Pfizer, Boehringer Ingelheim, UCB, Novartis and others. Its Series B round was led by Seoul-based DreamCIS, which supports biopharma R&D through extensive research services.
“We are thrilled to partner with DreamCIS, who shares our conviction that drug discovery urgently needs more human-relevant data at the preclinical stage,” said Michael Cho, Curi Bio’s chief strategy officer, in a statement. “The vast majority of new drugs fail in human clinical trials because preclinical animal and 2D cell models have failed to be good predictors of human outcomes.”
Curi Bio’s platform integrates bioengineered tissues created from induced pluripotent stem cells (iPSCs) with data collection and analysis. The additional funding will expedite its development of new platforms for cardiac, skeletal muscle, metabolic, smooth muscle and neuromuscular diseases, the company said.
The Seattle area is a hub of life science and biotech companies, including numerous efforts focused on AI-assisted research. Researchers have emphasized the need to test computer-generated drug candidates in the lab to verify their capabilities and impacts.
“Curi Bio’s unique integration of cells, systems, and data is a paradigm shift for preclinical drug discovery,” said Jeounghee Yoo, CEO of DreamCIS. “We were incredibly impressed by the company’s innovative platforms and their ability to generate functional data from 3D human tissues at scale.”
Curi Bio has raised more than $32 million from investors and $12 million from federal grants.
The company spun out of the University of Washington a decade ago as NanoSurface Biomedical. In April, Curi Bio celebrated the opening of its new 13,942-square-foot headquarters and research facility on the Seattle waterfront.
